Kevin Chow
Corporate Officer/Principal bei ALSP ORCHID ACQUISITION CORPORATION I
Profil
Kevin Chow is the founder of Vitaeris, Inc. founded in 2016, where he held the titles of President, Chief Executive Officer & Director until 2020.
He is currently an Operating Partner at Accelerator Services Corp since 2020, President at Incisive Genetics, Inc. since 2021, and Chief Business Officer at ALSP Orchid Acquisition Corp.
I.
Dr. Chow's former positions include Director-Business Development at Corus Pharma, Inc., Senior Director & Head-Business Development and Director at Lundbeck Seattle BioPharmaceuticals, Inc. from 2009 to 2016.
Dr. Chow's education includes undergraduate, graduate, and doctorate degrees from the University of British Columbia.
Aktive Positionen von Kevin Chow
| Unternehmen | Position | Beginn |
|---|---|---|
| ALSP ORCHID ACQUISITION CORPORATION I | Corporate Officer/Principal | - |
Incisive Genetics, Inc.
 Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | President | 07.06.2021 |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Private Equity Investor | 01.09.2020 |
Ehemalige bekannte Positionen von Kevin Chow
| Unternehmen | Position | Ende |
|---|---|---|
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Founder | 01.08.2020 |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 30.07.2016 |
| ALDER BIOPHARMACEUTICALS, INC. | Director/Board Member | 01.06.2016 |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Kevin Chow
| University of British Columbia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Corus Pharma, Inc.
Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Incisive Genetics, Inc.
Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | Health Technology |
ALSP Orchid Acquisition Corp. I
 ALSP Orchid Acquisition Corp. I Financial ConglomeratesFinance ALSP Orchid Acquisition Corp. I is a blank check company. It was formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase or other similar business combination, one or more operating businesses. The company was founded on August 31, 2021 and is headquartered in Seattle, WA. | Finance |
